

Hepatology COVID-19 Registry Week 13 Report


3 new cases added to the report since last week

| | Liver disease, Non-Transplant (N=25) | Post-liver transplantation (N=23) |
|---|---------------------------------------|-----------------------------------|
| Gender (%) | Female = 10 (40 %) | Female = 10 (43.47 %) |
| | Male = 15 (60 %) | Male = 13 (56.53 %) |
| Median Age (yr) at time of COVID diagnosis (range) | 5 (0.16-20) | 13 (0.5-21) |
| Etiology of liver disease | Biliary atresia = 7 | Biliary atresia = 8 |
| | NAFLD = 5 | Acute liver failure = 6 |
| | Autoimmune hepatitis = 5 | Metabolic disorders = 2 |
| | Acute Liver Failure = 2 | Tumor = 2 |
| | Metabolic disorder = 1 | Others** = 5 |
| | Others* = 5 | |
| Highest level of care | | |
| Outpatient | 7 | 16 |
| Hospital floor | 9 | 3 |
| ICU | 9 | 4 |
| Immunosuppression at time | No Immunosuppression = 20 | Tacrolimus = 19 |
| of COVID diagnosis | Azathioprine = 5 | Steroids = 9 |
| (*some patients were on multiple | Steroids =3 | Mycophenolate Mofetil = 8 |
| agents) | | Sirolimus = 3 |
| | | Azathioprine = 1 |
| | | Cyclosporine =1 |
| Specific Treatment for COVID | Hydroxychloroquine + Azithromycin = 3 | Hydroxychloroquine = 2 |
| (*some patients were on multiple | IVIG = 4 | Azithromycin = 1 |
| agents) | Steroids = 3 | IVIG = 1 |
| | Remdesivir = 2 | Favipiravir = 1 |
| | Tocilizumab + Sarilumab = 2 | Convalescent Plasma = 2 |
| | Eculizimab = 2 | Remdesivir = 1 |
| | Convalescent Plasma = 1 | Steroid (Dexamethasone) = 1 |
| | Anakinra = 1 | |
| Highest respiratory support | | |
| None | 17 | 20 |
| Nasal cannula/CPAP/BiPAP | 3 | 2 |
| Mechanical ventilation | 4 | 0 |
| High Frequency Oscillatory ventilation | 1 | 0 |
| Pending information | - | 1 |
| Final clinical outcome | | |
| Death | 1*** | 0 |
| Recovery | 21 | 19 |
| | | |
| Still active in clinical course | 2 | 3 |
| Still active in clinical course Pending information | 2 1 | 3 1 |
| | | |
| Pending information | 1 | |

*Others CLD: idiopathic cholestasis, GVHD/vanishing bile duct syndrome (Post BMT), IFALD with biliary obstruction, PFIC


 $\ensuremath{^{**}}$ Others PLT: IFALD , Congenital hepatic fibrosis, AIH-Sclerosing cholangits

Presenting symptoms at time of diagnosis



^{*}Constitutional symptoms reported: Loss of smell/taste , fever, myalgia, fatigue, sore throat # Other symptoms reported: Malaise, anorexia, headache, rash, Kawasaki disease like presentation(MIS-C)

Change done to Immunosuppressive agent (Post LT)



^{*}Stopped, decreased the dose, others and No changes Commonest agent **stopped**: Mycophenolate Mofetil